Pediatric Praziquantel Consortium

Publication: Sensitive diagnostic tools and targeted drug administration strategies needed to eliminate schistosomiasis

18 May 2020

While current treatment strategies have been instrumental in managing the disease burden of schistosomiasis, there...

COVID-19 and the Pediatric Praziquantel Consortium

24 April 2020

Over the last few weeks, the Pediatric Praziquantel Consortium has been working hard to map the...

A new formulation to fight Schistosomiasis


A pediatric formulation of Praziquantel has been developed for schistosomiasis.
Video credits: The GHIT Fund

Vision

Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more

Mission

Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

The consortium established a pediatric drug development program, divided into three major steps: preclinical development, clinical development and registration and access.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.

Read more